Table 1

Baseline clinical characteristics of the population from selected studies

TrialYearTreatmentNAge
(mean±SD),
median (IQR)
Age >75MalesHypertensionDiabetesHeart failureStrokeCHADS2≥2Control
LAAC trials
 PREVAIL2014Watchman26974.0±7.4140182238916374248Warfarin
 PROTECT-AF2013Watchman46371.7±8.819032641511312482307Warfarin
NOAC trials
 ENGAGE-AF2013Edoxaban14 06972 (64–78)5654867013 166510380763982NAWarfarin
 J-ROCKET-AF2012Rivaroxaban63971 (34–89)252530508249264NA639Warfarin
 ROCKET-AF2011Rivaroxaban713173 (65–78)NA430064362878446739167130Warfarin
 ARISTOTLE2011Apixaban912070 (63–76)2850598679622284323517486020Warfarin
 RELY2009Dabigatran12 09171.5±8.8NA770595332811387124288174Warfarin
 PETRO2007Dabigatran43270.0±8.313935230711112374NAWarfarin
WARFARIN trials
 PREVAIL2014Warfarin13874.9±7.278103134413239126LAAC
 PROTECT-AF2013Warfarin24472.7±9.2115171220726649178LAAC
 ENGAGE-AF2013Warfarin703672 (64–78)282045756588252140481991NAEdoxaban
 J-ROCKET-AF2012Warfarin63971.2 (43–90)246500508237257NA639Rivaroxaban
 ROCKET-AF2011Warfarin713373 (65–78)NA430164742817444138957131Rivaroxaban
 ARISTOTLE2011Warfarin908170 (63–76)2828589979542263321617905998Apixaban
 RELY2009Warfarin602271.6±8.6NA380947501410192211954163Dabigatran
 PETRO2007Warfarin7069.0±8.3195949152413NADabigatran
 BAFTA2007Warfarin48881.5±4.3488267259689664139Aspirin
 WASPO2007Warfarin3683.5 (80–90)NA141719NANAAspirin
 Vemmos et al242006Warfarin1680.1±2.5NA71021NANAAspirin
 ACTIVE-W2006Warfarin337170.2±9.5NA221127677171040510NADAPT
 WARSS2001Warfarin110363.3±11.2NA656746367NA321NAAspirin
 PATAF1999Warfarin13175.2NA584625NANANAAspirin
 AFASAK II1999Warfarin17074.2±7.7NA9780NANA9NAAspirin
 SPAF II 1994Warfarin19764±8
80±3
NANANANANANANAAspirin
 EAFT1993Warfarin22571.0±7.0NA124972718NANAPlacebo/aspirin
 SPAF1991Warfarin2106717155103252917NAPlacebo
 AFASAK1989Warfarin33572.8 (41–88)NA1761082516816NAPlacebo/aspirin
ANTIPLATELET trials
 BAFTA2007Aspirin48581.5±4.2485264269619460136Warfarin
 WASPO2007Aspirin3982.6 (80–90)NA2118210NANAWarfarin
 Vemmos et al242006Aspirin1579.5±2.9NA91112NANAWarfarin
 ACTIVE W2006DAPT333570.2±9.4NA22192755712991510NAWarfarin
 WARSS2001Aspirin110362.6±11.4NA653753338NA308NAWarfarin
 PATAF1999Aspirin14175.2NA675321NANANAWarfarin
AFASAK II1999Aspirin16973.1±7.2NA11073NANA9NAWarfarin
 SPAF II 1994Aspirin18864±8
80±3
NANANANANANANAWarfarin
 EAFT1993Aspirin40473.0±8.0NA2381985344NANAWarfarin
 AFASAK1989Aspirin33675.1 (40–91)NA1841122618312NAWarfarin
PLACEBO trials
 EAFT1993Placebo37873.0±8.0NA2001784945NANAWarfarin
 SPAF1991Placebo21167.017148116404017NAWarfarin
 AFASAK1989Placebo33674.6 (38–91)NA1801033317015NAWarfarin
  • DAPT, dual antiplatelet therapy; IQR, interquartile range; LAAC, left atrial appendage closure; NA, not available; SD, standard deviation.